Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • O Nedić, University of Belgrade, Serbia
  • Suresh Rattan
  • T Grune, Friedrich Schiller University Jena, Germany
  • I P Trougakos, National and Kapodistrian University of Athens, Greece
Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the Maillard chemical process of non-enzymatic glycation of free amino groups of proteins, lipids and nucleic acids. This chemical modification of biomolecules is triggered by endogeneous hyperglycaemic or oxidative stress-related processes. Additionally, AGEs can derive from exogenous, mostly diet-related, sources. Considering that AGE accumulation in tissues correlates with ageing and is a hallmark in several age-related diseases it is not surprising that the role of AGEs in ageing and pathology has become increasingly evident. The receptor for AGEs (RAGE) is a single transmembrane protein being expressed in a wide variety of human cells. RAGE binds a broad repertoire of extracellular ligands and mediates responses to stress conditions by activating multiple signal transduction pathways being mostly responsible for acute and/or chronic inflammation. RAGE activation has been implicated in ageing as well as in a number of age-related diseases, including atherosclerosis, neurodegeneration, arthritis, stoke, diabetes and cancer. Here we present a synopsis of findings that relate to AGEs-reported implication in cell signalling pathways and ageing, as well as in pathology. Potential implications and opportunities for translational research and the development of new therapies are also discussed.
Original languageEnglish
JournalFree Radical Research
Pages (from-to)28-38
Number of pages11
Publication statusPublished - 1 Aug 2013

See relations at Aarhus University Citationformats

ID: 55709449